Company: NCEL
Filing Date: 2025-03-31
Form Type: 425
Source: 0001213900-25-025889
Chunk: 260

Company: NewcelX Ltd.
Filing Date: 2025-03-31
Form: 425
Chunk 260
---
 annual report on Form
20-F for the year ended December 31, 2023 filed with the Securities and Exchange Commission (SEC), which is available on the SEC’s
website, www.sec.gov, and in subsequent filings made by NLS with the SEC.

<div align='center'>3</div>

No Offer or Solicitation

This communication is not intended to and shall
not constitute an offer to buy or sell or the solicitation of an offer to buy or sell any securities, or a solicitation of any vote or
approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior
to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made, except by
means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.

Additional Information about the Transaction and Where to Find It

In connection with the proposed transaction, NLS
has filed a Registration Statement on Form F-4, including a proxy statement/prospectus, with the SEC. NLS may also file other relevant
documents with the SEC regarding the proposed transaction. This document is not a substitute for the proxy statement/prospectus or any
other document that NLS may file with the SEC. The proxy statement (if and when available) will be mailed or delivered to shareholders
of NLS and Kadimastem. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE PROXY STATEMENT/PROSPECTUS AND ANY OTHER RELEVANT DOCUMENTS
THAT MAY BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY IF AND WHEN
THEY BECOME AVAILABLE BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION. Investors and security
holders will be able to obtain free copies of the proxy statement/prospectus (if and when available) and other documents containing important
information about NLS and Kadimastem and the proposed transaction, once such documents are filed with the SEC through the website maintained
by the SEC at http://www.sec.gov. Copies of the documents filed with the SEC by the Company will be available free of charge on NLS’s
website at www.nlspharma.com.

Participants in the Solicitation

NLS, Kadimastem, and certain of their respective
direct